Literature DB >> 19327767

Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.

Ning Xu1, Kent D Taylor, Ricardo Azziz, Mark O Goodarzi.   

Abstract

OBJECTIVE: To study the role of genetic variation in the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGCR) gene in polycystic ovary syndrome (PCOS).
DESIGN: Women with and without PCOS were genotyped for seven single-nucleotide polymorphisms (SNPs) in HMGCR. The SNPs and haplotypes were determined and tested for association with PCOS and its component traits.
SETTING: Subjects were recruited from the reproductive endocrinology clinic at the University of Alabama at Birmingham; control subjects were recruited from the surrounding community. Genotyping took place at Cedars-Sinai Medical Center in Los Angeles. PATIENT(S): A total of 287 white PCOS women and 187 control subjects were studied. INTERVENTION(S): Phenotypic and genotypic assessment. MAIN OUTCOME MEASURE(S): HMGCR genotype, PCOS diagnosis, androgen levels, metabolic traits. RESULT(S): No association with PCOS was observed. SNP rs4629571 was associated with increased insulin resistance. Haplotype 3 was associated with increased insulin resistance. Haplotype 5 was associated with higher SHBG and lower free T. CONCLUSION(S): Variation in the HMGCR gene may influence component features of PCOS, including insulin resistance, SHBG, and free T. HMGCR may thus act as a modifier gene in PCOS. Copyright (c) 2010 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327767      PMCID: PMC3032056          DOI: 10.1016/j.fertnstert.2009.01.158

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  25 in total

1.  Allelic discrimination using fluorogenic probes and the 5' nuclease assay.

Authors:  K J Livak
Journal:  Genet Anal       Date:  1999-02

2.  Partition-ligation-expectation-maximization algorithm for haplotype inference with single-nucleotide polymorphisms.

Authors:  Zhaohui S Qin; Tianhua Niu; Jun S Liu
Journal:  Am J Hum Genet       Date:  2002-11       Impact factor: 11.025

3.  Haploview: analysis and visualization of LD and haplotype maps.

Authors:  J C Barrett; B Fry; J Maller; M J Daly
Journal:  Bioinformatics       Date:  2004-08-05       Impact factor: 6.937

4.  Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.

Authors:  R S Legro; A R Kunselman; A Dunaif
Journal:  Am J Med       Date:  2001-12-01       Impact factor: 4.965

5.  Correct homeostasis model assessment (HOMA) evaluation uses the computer program.

Authors:  J C Levy; D R Matthews; M P Hermans
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

6.  Determination and use of haplotypes: ethnic comparison and association of the lipoprotein lipase gene and coronary artery disease in Mexican-Americans.

Authors:  Mark O Goodarzi; Xiuqing Guo; Kent D Taylor; Manuel J Quiñones; Carlos Samayoa; Huiying Yang; Mohammad F Saad; Aarno Palotie; Ronald M Krauss; Willa A Hsueh; Jerome I Rotter
Journal:  Genet Med       Date:  2003 Jul-Aug       Impact factor: 8.822

7.  Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study.

Authors:  Cemil Kaya; Sevim Dinçer Cengiz; Bülent Berker; Selda Demirtaş; Mustafa Cesur; Gürbüz Erdoğan
Journal:  Fertil Steril       Date:  2008-08-09       Impact factor: 7.329

8.  The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study.

Authors:  Thozhukat Sathyapalan; Eric S Kilpatrick; Anne-Marie Coady; Stephen L Atkin
Journal:  J Clin Endocrinol Metab       Date:  2008-10-21       Impact factor: 5.958

9.  Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation.

Authors:  Leslee J Shaw; C Noel Bairey Merz; Ricardo Azziz; Frank Z Stanczyk; George Sopko; Glenn D Braunstein; Sheryl F Kelsey; Kevin E Kip; Rhonda M Cooper-Dehoff; B Delia Johnson; Viola Vaccarino; Steven E Reis; Vera Bittner; T Keta Hodgson; William Rogers; Carl J Pepine
Journal:  J Clin Endocrinol Metab       Date:  2008-01-08       Impact factor: 5.958

10.  Relative impact of insulin resistance and obesity on cardiovascular risk factors in polycystic ovary syndrome.

Authors:  Mark O Goodarzi; Stephen Erickson; Sidney C Port; Robert I Jennrich; Stanley G Korenman
Journal:  Metabolism       Date:  2003-06       Impact factor: 8.694

View more
  2 in total

1.  PharmGKB: very important pharmacogene--HMGCR.

Authors:  Marisa Wong Medina; Katrin Sangkuhl; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-02       Impact factor: 2.089

2.  Effects of Androgen Excess-Related Metabolic Disturbances on Granulosa Cell Function and Follicular Development.

Authors:  Baoying Liao; Xinyu Qi; Chuyu Yun; Jie Qiao; Yanli Pang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-14       Impact factor: 5.555

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.